Peer-reviewed veterinary case report
Benazepril delays heart disease progression in Doberman Pinschers
By O'Grady, M R et al.·Published in Journal of veterinary internal medicine·2009·Department of Clinical Studies, Canada·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers.
- Species:
- dog
Plain-English summary
A group of 91 Doberman Pinschers with early signs of heart disease (occult dilated cardiomyopathy) were treated with a medication called benazepril hydrochloride to see if it could delay the progression to more severe heart disease. The dogs receiving benazepril showed a significantly longer time before developing overt heart disease compared to those not receiving the medication. This suggests that benazepril may help slow down the worsening of heart problems in these dogs. If your Doberman has been diagnosed with occult DCM, discussing benazepril with your vet could be beneficial.
People also search for: Doberman heart disease treatment · benazepril for dogs · occult dilated cardiomyopathy in dogs
Abstract
BACKGROUND: Angiotensin converting enzyme inhibitors (ACEIs) are recommended in people to treat asymptomatic (occult) dilated cardiomyopathy (DCM). Efficacy of therapy in occult DCM in dogs is unknown. HYPOTHESIS: ACEIs, specifically benazepril hydrochloride (BH), will delay the onset of overt DCM in Doberman Pinschers. ANIMALS: Ninety-one Doberman Pinschers were studied, 57 dogs received BH, and 34 dogs no ACEI. METHODS: Retrospective study of the medical records of all Doberman Pinschers with occult DCM that received BH or no ACEI between April 1989 and February 2003. Two criteria of left ventricular enlargement were used for enrollment: one independent of body weight (BW) (C1) and the other indexed to BW (C2). Cox proportional hazards analyses were used to identify variables associated with the onset of overt DCM. RESULTS: On univariate analysis the median time to onset of overt DCM was significantly longer for the benazepril group (for C1: 425 days for BH, 95% confidence interval [CI] 264-625 days; 339 days for no ACEI, CI 172-453 days, P= .02; for C2: 454 days for BH, CI 264-628 days; 356 days for no ACEI, CI 181-547 days, P= .02). The hazard ratio (HR) (benazepril/no ACEI) was 0.57, CI 0.35-0.94, P= .03 for C1; HR = 0.56, CI 0.34-0.93, P= .02 for C2. On multivariate analysis, BH significantly delayed onset of overt DCM (HR [benazepril/no ACEI] = 0.45, CI 0.26-0.78, P < .01, for C1; HR = 0.36, CI 0.21-0.63, P < .01, for C2). CONCLUSIONS: BH in particular and ACEIs in general might delay the progression of occult DCM. Prospective studies are warranted to test this theory.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/19572914/